Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio 6 May 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces that it has co-led a $45 million Series B financing round in Nuevocor, an IND-stage biotechnology company specialized in the development of

May 05, 2025 -- Brain Cancer Canada is pleased to announce a $85,000 grant for a cutting-edge research initiative led by Dr. Leonardo Salmena at the University of Toronto. The project, titled “Exploring microRNA as Targets for Glioblastoma Therapy”, focuses on developing novel therapeutic strategies to address one of the most aggressive and treatment-resistant forms of brain cancer. Glioblastoma (GBM) is the most common and lethal brain malignancy in adults, with fewer than 5% of patients surv

AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications The company will present at upcoming medical meetings, AACR and ASCO April 24, 2025 -- Avidicure, a biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology,

New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society New preclinical data highlighting potential of CY-101 in ACC and other cancer types driven by a dysfunctional Wnt/β-catenin pathway, including colorectal cancer, to be presented at AACR annual meeting April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its firs

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management March 27, 2025 -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of next-generation diagnostics. Secured $25M in funding from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI Ventures, AME Cloud, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics. March 27, 2025 -- Galatea Bio, a leader in AI-driven genomic research and clinical genetic testing has secured $25 million in funding to drive discove

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics and reverse transcriptase (RT)-based editing programs March 18, 2025 -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines,

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair March 17, 2025 -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines

Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this round Proceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Opens way for clinical development across multiple medically important neuro-urology pathologies Funding will also support the company’s early-stage pipeline based on its proprietary HERMES vector technology platform. February 20, 2025 – EG 427, a biotechnology co

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas (CPRIT) Feb. 18, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company,” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced today that it has closed a private placement with aggregate initial upfront p